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Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that lacks a predictive and broadly
applicable biomarker. Continued focus on mutation-specific upstream mechanisms has yet to predict disease
progression in the clinic. Utilising cellular pathology common to the majority of ALS patients, we implemented an
objective transcriptome-driven approach to develop noninvasive prognostic biomarkers for disease progression.
Genes expressed in laser captured motor neurons in direct correlation (Spearman rank correlation, p < 0.01) with
counts of neuropathology were developed into co-expression network modules. Screening modules using three
gene sets representing rate of disease progression and upstream genetic association with ALS led to the prioritisation
of a single module enriched for immune response to motor neuron degeneration. Genes in the network module
are important for microglial activation and predict disease progression in genetically heterogeneous ALS cohorts:
Expression of three genes in peripheral lymphocytes - LILRA2, ITGB2 and CEBPD – differentiate patients with rapid and
slowly progressive disease, suggesting promise as a blood-derived biomarker. TREM2 is a member of the network
module and the level of soluble TREM2 protein in cerebrospinal fluid is shown to predict survival when measured in
late stage disease (Spearman rank correlation, p = 0.01). Our data-driven systems approach has, for the first time,
directly linked microglia to the development of motor neuron pathology. LILRA2, ITGB2 and CEBPD represent
peripherally accessible candidate biomarkers and TREM2 provides a broadly applicable therapeutic target for ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenera-
tive disease without effective treatment or a predictive
biomarker [50]. Progressive motor neuron loss leads to a
median survival of only 32 months, with death most
often the result of respiratory failure [42]. A useful non-
invasive biomarker for ALS progression should antici-
pate disease severity in advance, be broadly applicable
independent of genetic background, and should provide
a basis for therapeutic intervention. Many biomarkers in
development currently are potentially limited because
they are phenomenological including electrophysio-
logical [14], imaging [19], clinical [41] and fluid-based
[29] measures. Other upstream markers are specific to rela-
tively rare genetic variants e.g. RNA foci and dipeptide-
repeat proteins in C9ORF72-ALS [8, 30].
Data-driven methods employing transcriptomics have
successfully identified biomarkers in other clinically and
genetically heterogeneous disease states, including breast
and gastric cancers, psoriasis and progressive supra-
nuclear palsy [26, 43, 48, 54]. To achieve a similar goal
we planned an approach with a discovery phase followed
by a biomarker phase. In the discovery phase, we utilised
a systematic, data-driven approach to discover and pri-
oritise modules of tightly co-expressed genes relevant to
ALS pathogenesis (Fig. 1a–c). In the biomarker assess-
ment phase we tested the capability of top performing
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modules as a biomarker (s) when measured in accessible
tissue (Fig. 1d).
In order to deconstruct central nervous system (CNS)
pathophysiology, studies have concentrated on a single
dysfunctional feature, an approach that may not yield
sufficiently broad insights into global disease mecha-
nisms. An advantage of a global transcriptome-based
analysis is the capacity to exhaustively describe a bio-
logical system without prior information [28]. Integrating
transcriptome profiling with measurement of a disease-
specific covariate reveals the contribution of individual
genes to pathogenesis [22]. Extending this concept to the
level of networks of interacting genes rather than isolated
genes provides further physiological insight [17].
The aim of our approach is to develop non-invasive,
broadly applicable prognostic biomarkers for ALS disease
progression. Although ALS is markedly heterogeneous
both genetically and phenotypically, more than 98% of ALS
patients develop p62- and TDP-43-positive neuronal cyto-
plasmic inclusions within degenerating motor neurons
[33]. Post-mortem studies have indicated that the fre-
quency of neuronal TDP-43-positive cytoplasmic aggre-
gates predicts the severity of neurodegeneration in a
region-specific manner [2]. We selected motor neuron
pathology as a covariate measure of disease severity which
could potentially be used to identify important, broadly ap-
plicable, transcriptome changes related to outcome.
To maximize signal from the relevant affected system,
gene expression profiling was performed on laser captured
motor neurons from ALS patients. Genes correlated in
their levels of expression with motor neuron pathology
were then developed into co-expression network modules
which were filtered and prioritised based on independently
curated markers of ALS biology: gene sets related to rate of
progression and upstream genetic association with ALS. In
the discovery phase (Fig. 1a–c) our systematic approach
led to identification of two gene modules enriched with
ALS biology. Functional enrichment within the top scoring
network module revealed genes which encode an immune
response to motor neuron pathology; the majority of these
genes are expressed by microglia.
Gene expression within the CNS has been observed in
peripheral tissues [18, 22] so in the biomarker assessment
phase (Fig. 1d) of our analysis, we explored the possibility
that our modules, generated from CNS tissue, may include
genes with tissue-independent ability to predict disease se-
verity. Components of the immune module were assessed
by mRNA and protein quantification in accessible tissues
such as blood and cerebrospinal fluid (CSF). We demon-
strate candidate biomarkers that provide insight into poten-
tial therapeutic targets.
Materials and methods
Laser captured motor neurons
Brain and spinal cord tissue from fourteen ALS patients
was obtained from the Sheffield Brain Tissue Bank
(Table 1). Seven of these patients carried a hexanucleo-
tide repeat expansion of C9ORF72 and seven patients
Fig. 1 Data-driven discovery workflow. Using anterior horn tissue, RNA transcript expression was measured from isolated motor neurons, and
counts of p62-positive cytoplasmic inclusions within motor neurons were conducted. RNA expression and pathology counts from the same patients were
correlated by Spearman’s rank correlation to identify 83 transcripts (a). Pathology correlated transcripts seeded co-expressed networks. The resulting
combined network was developed into tightly co-expressing modules using weighted gene co-expression analysis (WGCNA) (b). Modules were
prioritised using enrichment with independently curated gene lists related to ALS rate of progression and ALS genetic susceptibility. The two top scoring
modules were enriched for neuronal and immune function respectively. MN =motor neuron, LB = lymphoblastoid (c). The immune module was selected
for use as a biomarker in peripheral tissue and additional non-tissue specific genes were added. Components of the immune module were assessed by
mRNA and protein quantification for predictive value in blood and cerebrospinal fluid (CSF) (d)
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suffered sporadic ALS with no identified pathogenic
mutation. C9ORF72-ALS samples were identified by
repeat-primed PCR of the C9ORF72 gene [9]. Common
mutations in C9ORF72, TARDBP, FUS, CHMP2B and
SOD1 were excluded in the sporadic ALS patients.
Tissue donated for research was obtained with written
informed consent from the next of kin, and in accord-
ance with the UK Human Tissue Authority guidelines on
tissue donation. The work was approved by the South
Yorkshire Ethics Committee.
Spinal cord sections from the limb enlargements were
collected postmortem, processed according to standard
protocols [21], and stored at −80 °C until required.
Cervical spinal cord sections were prepared, between
800 and 1200 motor neurons were isolated, and RNA
was extracted using methods described previously [15].
RNA quantity and quality was assessed on the Nanodrop
spectrophotometer and Agilent Bioanalyser, respectively,
to ensure all samples were of comparable and sufficient
quality to proceed. RNA (20–25 ng) was linearly ampli-
fied using the Affymetrix Two Cycle cDNA synthesis
protocol to produce biotin-labelled copy RNA. Copy
RNA (15 μg) was fragmented for 15 min and hybridized
to the Human Genome U133 Plus 2.0 GeneChips, ac-
cording to Affymetrix protocols. Array washing and
staining was performed in the GeneChip® fluidics station
400 and arrays were scanned on the GeneChip® 3000
scanner. GeneChip® Operating Software was used to
generate signal intensities for each transcript.
Lymphoblastoid cell lines
Lymphoblastoid cell lines derived from 46 Caucasian
ALS patients, all of Northern European descent, were
obtained from the UK Motor Neurone Disease Associ-
ation DNA Bank (Table 2). C9ORF72-ALS samples were
identified by repeat-primed PCR of the C9ORF72 gene
[9]. All samples were collected with written informed
consent from the donor, and the work was approved by
the South Yorkshire Ethics Committee.
Total RNA was extracted from ALS patient and control-
derived lymphoblastoid cell lines using QIAGEN’s RNeasy®
Mini Kit following the manufacturer’s recommendations.
A 75 μL LCL suspension, containing approximately 5x106
cells, typically yields between 1.9 and 13.6 μg total RNA
with a mean concentration of approximately 170 ng/μl as
assessed the by the NanoDrop 1000 spectrophotometer
(Thermo Scientific). The quality of the isolated material
was analysed using the 2100 bioanalyzer with an RNA
6000 Nano LabChip® Kit (Agilent Technologies, Inc.).
Linear amplification of RNA with an input of approxi-
mately 300 ng of starting material was performed using
the Ambion® Whole Transcript (WT) Expression Assay
(Applied Biosystems) and Affymetrix GeneChip® WT
Terminal Labelling Kit. This procedure generated
fragments of biotin-labelled sense-stranded copy DNA
(6–10 μg) between 40 and 70 nucleotides in length that
were hybridized onto Human Exon 1.0ST GeneChip®
Arrays according to Affymetrix protocols. Array wash-
ing, staining and visualisation were performed as de-
scribed for motor neuron derived RNA.
Immunohistochemistry
Cervical spinal cord anterior horn was examined from
11 ALS patients including seven C9ORF72-ALS pa-
tients and four patients with sporadic ALS (Table 1,
Table 1 Clinical information relating to motor neurons laser captured from ALS patients
ID Gender Age at onset (years) Disease duration (years) Site of onset C9ORF72 status Familial/Sporadic
1 M 70 2.17 Limb + Familial
2 M 66 1.17 Bulbar + Familial
3 F 56 3.58 Limb + Familial
4 F 61 3.33 Bulbar + Sporadic
5 F 58 0.58 Limb + Sporadic
6 M 62 1.67 Bulbar + Sporadic
7 F 61 3.50 Limb + Sporadic
8 M 60 3.17 Limb - Sporadic
9 M 71 0.75 Limb - Sporadic
10 M 49 2.42 Limb - Sporadic
11 M 74 5.25 Limb - Sporadic
12 M 71 4.00 Limb - Sporadic
13 M 69 3.92 Limb - Sporadic
14 M 50 2.08 Limb - Sporadic
C9ORF72 status indicates the presence (+) or absence (-) of a GGGGCC-repeat expansion in the C9ORF72 gene
M Male, F Female
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Table 2 Clinical information relating to lymphoblastoid cell lines derived from ALS patients
ID Gender Age at onset (years) Disease duration (years) Site of onset C9ORF72 status Familial/Sporadic
1 F 28 1.10 Bulbar + Familial
2 F 57 1.21 Mixed + Familial
3 F 62 0.17 Bulbar + Familial
4 M 59 <1 year N/A + Familial
5 M 63 1.71 Mixed + Familial
6 M 47 1.63 Limb + Familial
7 F 51 0.97 Bulbar + Familial
8 M 60 1.15 Bulbar + Sporadic
9 M 68 1.56 Limb + Sporadic
10 F 37 1.74 Limb + Sporadic
11 M 56 2.20 Limb + Sporadic
12 M 45 1.47 Limb + Sporadic
13 M 72 0.52 Limb + Sporadic
14 F 58 1.33 Mixed + Sporadic
15 M 47 1.57 Limb + Sporadic
16 M 64 0.66 Limb + Sporadic
17 M 62 1.96 Limb + Sporadic
18 M 65 1.40 Limb + Sporadic
19 F 69 >4 years Limb + Familial
20 M 63 >5 years Limb + Familial
21 F 64 6.92 Limb + Familial
22 F 56 4.14 Limb + Familial
23 F 72 4.66 Limb + Sporadic
24 F 48 5.95 Limb + Sporadic
25 F 37 4.50 Bulbar + Sporadic
26 M 61 ~4 years Mixed + Sporadic
27 M 44 0.94 Mixed - Sporadic
28 M 54 5.90 Limb - Sporadic
29 M 72 5.99 Limb - Sporadic
30 M 76 0.85 Limb - Sporadic
31 F 76 1.08 Bulbar - Sporadic
32 F 65 1.10 Limb - Sporadic
33 M 65 7.70 Limb - Sporadic
34 M 49 0.39 Limb - Sporadic
35 M 32 6.05 Limb - Sporadic
36 M 35 6.85 Limb - Sporadic
37 F 62 0.73 Bulbar - Sporadic
38 F 58 6.02 Limb - Sporadic
39 M 66 0.85 Limb - Sporadic
40 M 82 6.67 Limb - Sporadic
41 F 75 0.89 Limb - Sporadic
42 M 49 0.70 Limb - Sporadic
43 F 68 6.17 Limb - Sporadic
44 F 62 6.69 Limb - Sporadic
45 M 71 7.12 Limb - Sporadic
46 M 86 1.04 Limb - Sporadic
C9ORF72 status indicates the presence (+) or absence (-) of a GGGGCC-repeat expansion in the C9ORF72 gene
M Male, F Female
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patients 1–11). Immunohistochemistry was performed
for p62 and phospho-TDP-43.
In staining for p62, slides were first deparaffinised
through two changes of xylene and hydrated through de-
creasing concentrations of alcohol (2×100%/1x95%/
1x70%). Antigen retrieval was achieved by boiling the
samples in trisodium citrate at pH 6.5, and endogen-
ous peroxidase was blocked in 3% H2O2 in methanol
for 20 min. The slides were then stained using the
VECTASTAIN Elite ABC Kit (Vector Laboratories,
California, US) following these incubation protocol:
serum 30 min RT, anti-p62 Ick ligand antibody (Cat.
610832, BD Transduction Laboratories, California,
US) 1 h RT, 2° biotinylated antibody 30 min RT, ABC
reagent 30 min RT, Vector DAB reagent 10 min, HCM
(Harry’s haematoxylin 2 min, Scott’s tap water until
blue colour, dehydration and clear through 70%/95%/
2x100% ethanol/2× xylene, mount in DPX).
In staining for phospho-TDP-43, deparaffinisation, hy-
dration and antigen retrieval were done in a pressure
cooker (Antigen Access Unit, A. Menarini, Berkshire,
UK) at pH 6 using the Access Citrate solution. Then, the
slides were stained using the A. Menarini Intellipath Kit
through the following incubation steps: Endogenous per-
oxidase block 5 min room temperature (RT), casein
background blocker 10 min RT, anti-phospho-TDP-43
antibody (Cat. TIP-PTD-M01, Cosmo Bio Co, Tokyo,
Japan) 1 h RT, universal probe 15 min RT, HRP-polymer
15 min RT, DAB chromogen 5 min RT, HCM.
Genome wide association study
ALS susceptibility genes were identified by a large
genome wide association study (GWAS) which used the
NeuroX chip [32] to genotype 3539 ALS cases and 5191
normal controls; the NeuroX chip includes genotyping
of standard Illumina exome content of approximately
240,000 variants, and additionally, more than 24,000
custom content variants to improve coverage in genes
associated with neurological diseases. Genes significantly
associated with ALS were unchanged when the analysis
was performed with the custom NeuroX chip content
removed to avoid potential bias. GWA on the NeuroX
collaboration was analysed using PLINK [37]. 267607
SNPs were analysed in 10081 founders (0 non-founders
identified). No SNPs failed frequency and genotyping
pruning. Association with ALS was determined by Chi2-
test; threshold for significance was set at an unadjusted
p-value of 5E-08 [4].
Alzheimer’s GWA genes were identified using GWAS
Central (http://www.gwascentral.org), which is a compil-
ation of summary level findings from genetic association
studies. 57 studies were identified containing the key-
word ‘Alzheimer’s’. Variants associated with Alzeimer’s
disease at a p-value <5E-08 and their associated genes
were identified.
Gene expression data analysis
Microarray data were normalised using the Puma pack-
age which quantifies technical variability to improve the
estimation of gene expression [27]. The significance of
association of transcript expression levels with continu-
ous variables such as pathology counts and disease
duration was determined by Spearman rank correlation.
Differential expression between two groups was deter-
mined by Mann–Whitney U-test. In the identification of
significant enrichment of gene list ‘x’ in gene list ‘y’ we
utilised Fisher’s exact test to calculate the probability
that the observed overlap occurred by chance.
Conversion between various gene/transcript identifiers
was performed using Affymetrix Human Genome U133
Plus 2.0 Array annotation data and BioMart [13].
Network detection was performed using weighted gene
coexpression analysis (WGCNA) [25]. Global interaction
partners of network genes were identified using co-
expression and proteomics data from the GeneMANIA
prediction server [52].
For the purpose of all analyses in lymphoblastoid cells
and in CSF, patients with disease duration <2 years were
defined as rapidly progressive and patients with disease
duration >4 years were defined as slowly progressive.
Measurement of soluble TREM2 in CSF
CSF concentrations of sTREM2 were measured using a
standard sandwich ELISA consisting of a biotinylated
polyclonal goat anti-human TREM2 capture antibody
(R & D Systems BAF1828); a monoclonal mouse anti-
human TREM2 detection antibody (R & D Systems
MAB1828); and a SULFO-TAG–labeled anti-mouse
secondary antibody (Meso Scale Discovery R32AC-1).
Recombinant human TREM2 protein (huTrem2-hIg-
G1aglyFc) was produced at Biogen in Chinese hamster
ovary (CHO) cells and purified by size-exclusion chro-
matography to remove aggregates since aggregated pro-
teins can lead to higher binding. Streptavidin-coated
96-well plates (Meso Scale Discovery L15SB) were
blocked overnight at 4 °C in blocking buffer [0.5% bo-
vine serum albumin (BSA) and 0.05% Tween 20 in PBS
(pH 7.4)]. The plates were then incubated with the cap-
ture antibody for 1 h at room temperature. Plates were
washed three times with washing buffer (0.05% Tween
20 in PBS) and incubated with the CSF samples diluted
1:4 or with a titration of recombinant human TREM2
protein (2000 ng/ml to 0.1 ng/ml) for 2 h at room
temperature. Plates were washed three times with wash-
ing buffer before incubation with the detection antibody
for 1 h at room temperature. After three additional washes,
plates were incubated with the secondary antibody for 1 h
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at room temperature. All incubation steps were performed
with gentle shaking. Plates were washed three times with
wash buffer, then the electrochemical signal was developed
by adding 2× Meso Scale Discovery Read buffer and the
light emission measured using the Mesoscale Discovery
SECTOR S 600.
All lumbar punctures were clinically indicated. We
aimed to compare levels of soluble TREM2 in CSF from
sporadic ALS patients to levels in normal controls. Pre-
viously it has been noted that levels of soluble TREM2
can be elevated in a number of inflammatory CNS
diseases [35]; therefore our criteria for selection of con-
trol cases were: normal CSF constituents and no evi-
dence of neuroinflammation. Diagnoses in control cases
included headache with normal CSF, medically unex-
plained symptoms and cerebrovascular disease. Controls
and patients (Table 3) were matched for age and sex;
mean age of controls was 51 years (range 34–74 years),
mean age of ALS patients was 58 years (range 32–83
years). Controls included 11 males and 9 females; ALS
patients included 28 males and 18 females. All samples
were collected with written informed consent from the
donor, and the work was approved by the South Yorkshire
Ethics Committee. Based on the time of sampling relative
to disease onset and time of death it was possible to iden-
tify at what point in the patients disease course CSF
sampling occurred. Early disease was defined as the first
25th-centile of all patients assayed and late disease was de-
fined as the last 25-centile of all patients assayed. In order
to minimise the effect of outliers statistical tests were per-
formed using ranks instead of actual values. Correlation
with clinical variables was determined by Spearman rank
correlation, and differences between groups were deter-
mined by Mann–Whitney U-test.
Results
We aimed to identify a set of genes that can predict ALS
disease progression when measured in tissues that are
core to disease, but also in tissues that are accessible
clinically. Our systems approach has two phases of in-
vestigation: a discovery phase (Fig. 1a–c) and a subse-
quent biomarker assessment phase (Fig. 1d).
Identifying correlates of neuropathology
To identify genes expressed in correlation with the num-
ber of proteinaceous inclusions within motor neurons
(pathology correlates), we performed targeted immuno-
histochemistry and gene expression profiling in ALS
motor neurons (Fig. 1a). Cervical spinal cord anterior
horn was examined from 11 ALS patients including seven
C9ORF72-ALS patients and four patients with sporadic
ALS (Table 1, patients 1–11). Total RNA was extracted
from isolated motor neurons and expression of 54,675 an-
notated transcripts was measured by microarray analysis.
In adjacent tissue from the same patients we counted
the number of motor neurons per unit area containing
a p62-positive cytoplasmic inclusion (Additional file 1:
Figure S1). Spearman rank correlation was calculated
between the expression of each transcript and the path-
ology counts. Eighty-three transcripts, corresponding to 59
genes, correlated with the quantity of pathology (p < 0.01)
(Additional file 2: Table S1).
Motor neuron inclusions in ALS are expected to stain
for TDP-43 and p62 [33]. We confirmed coincidence of
p62- and TDP-43-positive staining in cervical cord from
the same cases. Presence of p62 and TDP-43 was signifi-
cantly correlated, despite measurement in non-overlapping
tissue sections (Spearman rank correlation, p < 0.05, Addi-
tional file 1: Figure S2).
Derivation of gene modules associated with
neuropathology
To explore their functional context, each of the 83
pathology-correlated transcripts were used as a seed to
identify transcripts with similar expression (top 1% of
transcripts by Pearson’s correlation, Fig. 1b). Transcripts
were combined into a single network, which was divided
into modules of highly correlated genes by weighted gene
co-expression analysis (WGCNA) [25, 55]. WGCNA is an
established method for module detection within gene co-
expression networks and has been previously applied in
biomarker development [48]. WGCNA analysis revealed
82 network modules of between 35 and 515 transcripts
(Additional file 1: Figure S3, Additional file 2: Table S1).
Forty-five network modules contained one or more of
the 83 pathology-correlate transcripts. The remaining
modules were discarded.
Systematic prioritisation of gene modules based on
enrichment with ALS biology
To identify which of the 45 gene modules have potential
as biomarkers we needed an independent and systematic
test of their relevance to ALS biology. For this purpose
three assessment gene sets were curated to represent
rate of progression and upstream genetic association
with ALS (Fig. 1c). A motor neuron gene set was gener-
ated from laser captured motor neurons (Table 1, pa-
tients 1–14); motor neurons were obtained from a set of
patients which overlapped but was distinct from the data
used to derive the 83 pathology-correlated transcripts. It
contained 1705 transcripts significantly correlated with
disease duration (p < 0.05) (Additional file 2: Table S2).
A lymphoblastoid cell gene set was generated from per-
ipherally accessible blood-derived lymphoblastoid cells
(Table 2 patients 1–26). It contained 4070 transcripts
differentially expressed between patients with rapidly
and slowly progressive disease (p < 0.05). (Additional
file 2: Table S3).
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Table 3 Clinical information relating to CSF samples obtained from sporadic ALS patients and controls
ALS/Control Gender Age at onset (years) Disease duration (years) Age at sample (years) Percentage of disease
course at CSF sampling
Soluble TREM2 (ng/ml)
ALS M 35.8 4.8 36.9 22.8% 309.6
ALS M 50.7 17.0 53.4 16.2% 2.6
ALS M 79.7 1.3 79.8 6.3% 10.3
ALS M 67.4 11.9 72.1 39.2% 10.8
ALS M 71.5 0.8 72.3 90.0% 5.7
ALS F 47.8 14.5 49.3 10.9% 3.6
ALS F 65.3 1.2 66.3 85.7% 7.9
ALS M 64.4 1.0 65.3 100.0% 6.9
ALS M 64.3 0.8 64.8 66.7% 2.3
ALS F 34.4 0.6 34.7 42.9% 4.7
ALS M 54.4 6.9 56.1 24.1% 9.0
ALS M 52.6 5.4 54.0 26.2% 27.4
ALS M 56.4 12.0 57.8 11.8% 4.2
ALS F 76.2 1.0 76.9 75.0% 4.9
ALS F 64.3 0.4 64.5 60.0% 8.1
ALS M 69.4 0.7 69.7 37.5% 37.7
ALS M 42.9 10.5 43.9 9.5% 5.3
ALS M 47.1 1.3 47.7 43.8% 18.4
ALS F 54.2 5.8 54.7 8.7% 14.5
ALS M 57.7 1.1 58.0 30.8% 14.8
ALS F 51.2 5.6 52.3 19.4% 22.8
ALS F 45.2 8.6 46.0 9.7% 8.6
ALS F 59.5 1.4 59.8 17.6% 9.9
ALS M 36.8 4.4 38.7 43.4% 8.5
ALS M 32.0 8.8 37.9 67.0% 18.2
ALS F 50.7 3.8 51.7 26.7% 2.9
ALS M 29.8 4.5 31.5 38.9% 2.8
ALS F 68.5 2.5 69.9 56.7% 4.0
ALS M 81.0 1.6 82.5 94.7% 4.3
ALS M 64.3 4.5 67.6 72.2% 25.1
ALS M 50.6 2.2 51.4 38.5% 16.5
ALS M 65.1 3.6 67.7 72.1% 9.7
ALS F 58.7 1.3 59.6 73.3% 16.0
ALS M 59.2 5.2 62.1 56.5% 9.4
ALS F 60.5 1.7 61.6 65.0% 24.8
ALS M 55.7 1.8 56.9 71.4% 16.2
ALS M 60.1 4.8 62.8 57.9% 9.0
ALS M 65.5 2.4 66.5 41.4% 5.1
ALS F 49.9 3.8 52.5 67.4% 17.1
ALS F Unavailable Unavailable 63.8 Unavailable 8.3
ALS F 52.9 3.4 54.3 41.5% 5.1
ALS M 50.8 2.6 51.4 25.8% 7.3
ALS F 62.1 7.7 68.3 80.4% 34.9
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The third assessment set was a genome wide association
gene set which consisted of 62 genes containing variants
(unadjusted asymptotic association test, p < 5E-08) associ-
ated with ALS in a genome wide association study
(GWAS) of 3539 ALS cases and 5191 normal controls
(Additional file 2: Table S4). Genetic variants associated
with ALS are by definition upstream. Modules enriched
with genetic determinants are more likely to be predictive
as genetic determinants are by definition upstream of a
disease that occurs in adulthood.
Three of the 45 modules were enriched with all three
assessment gene sets (Fig. 2, modules 1, 25 and 27).
Module 25 was the most highly enriched with the motor
neuron gene set (p = 1.92E-20) and module 27 was the
most highly enriched with the lymphoblastoid gene set
(p = 7.82E-21). Both module 25 and 27 were significantly
enriched with ALS GWA genes (p value < 0.05). Module
25 and 27 were selected for further characterisation.
To determine whether modules 25 and 27 captured
aspects of disease pathogenesis or simply show motor
neuron-specific gene expression, we constructed a nega-
tive control from an artificial module consisting of genes
which are expressed specifically in non-diseased motor
neurons [12] (Additional file 2: Table S1). The negative
control module was not enriched with the assessment
gene set derived from motor neurons or with ALS GWA
genes; there was limited enrichment with the lympho-
blastoid gene set (p = 0.001). Modules 25 and 27 showed
significantly better enrichment with ALS biology gene
sets than the negative control module.
Functional characterisation of modules
As modules 25 and 27 showed significant enrichment with
ALS biology gene sets we sought to determine the function
of genes in these modules (Fig. 1c). Module 25 enriched for
the Gene Ontology (GO) biological process categories ‘syn-
aptic transmission, cholinergic’ and ‘response to oxygen
stimulus’ (g: Profiler, corrected p-value = 0.04) [40]. Module
27 enriched for the GO category ‘immune system process’
(corrected p-value = 7.32E-07). Module 27 will henceforth
be referred to as the immune module.
Enrichment within module 27 of immune-associated
genes suggests that glial cells proximal to diseased motor
neurons may have been laser captured alongside ex-
tracted motor neurons. To explore which glial cells
might have been isolated we examined cell-specific
Table 3 Clinical information relating to CSF samples obtained from sporadic ALS patients and controls (Continued)
ALS M 32.9 2.6 33.9 38.7% 4.7
ALS F 47.3 1.7 47.8 30.0% 4.4
ALS M 66.6 3.9 69.6 76.6% 7.9
Control M NA NA 828 NA 4.0
Control M NA NA 407 NA 6.5
Control F NA NA 717 NA 10.6
Control F NA NA 671 NA 7.0
Control F NA NA 628 NA 2.9
Control M NA NA 573 NA 3.4
Control F NA NA 542 NA 2.6
Control F NA NA 563 NA 4.8
Control M NA NA 455 NA 5.9
Control M NA NA 586 NA 4.8
Control M NA NA 473 NA 14.2
Control F NA NA 587 NA 3.1
Control F NA NA 594 NA 12.9
Control M NA NA 886 NA 9.4
Control M NA NA 782 NA 14.7
Control M NA NA 553 NA 12.3
Control M NA NA 502 NA 5.1
Control F NA NA 701 NA 8.9
Control M NA NA 673 NA 6.7
Control F NA NA 475 NA 3.4
M Male, F Female
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expression of module 27 genes using a reference data-
base of transcriptome data from isolated human brain cell
lines (http://web.stanford.edu/group/barres_lab/brainseq
Mariko/brainseq2.html). Genes within the immune mod-
ule were classified as expressed in one or more of micro-
glia/macrophage cells, astrocytes and oligodendrocytes
(Additional file 2: Table S5). 61% of the genes in the im-
mune module are known to be expressed in human
microglia/macrophage cells as compared to 30% in mature
astrocytes and 17% in oligodendrocytes. The majority of
immune module genes are expressed in microglia/macro-
phage cells rather than alternative glial subtypes.
Development of immune module (module 27) into a
peripheral tissue biomarker
A clinically translatable biomarker needs to be measurable
in accessible tissue. Markers of inflammation associated
with neurodegeneration have been observed in blood [44]
and CSF [31]. Module 27 (the immune module) was
highly enriched with the assessment set containing genes
associated with disease progression in lymphoblastoid
cells (p = 7.82E-21). We chose to focus on the immune
module for biomarker development.
To reduce neuron-specific signal and improve likelihood
of detecting genes expressed in the immune module in
peripheral tissues, we added tissue-independent globally
co-expressed genes and protein-protein interacting part-
ners [11] using a database of broadly co-expressed genes
with functional association data (GeneMANIA) [52]
(Fig. 1d). The immune module was expanded from 65 to
77 genes (Fig. 3). We tested the expanded module against
the assessment gene sets representing rate of ALS disease
progression and showed an improvement in biomarker
performance. The module showed improved enrichment
with gene sets related to rate of disease progression in
motor neurons gene (p = 6.14E-03 from 4.56E-02), and in
lymphoblastoid cells (p = 1.94E-32 from 7.82E-21).
Assessment of immune module as a potential biomarker
in blood
To provide evidence in support of the immune module
as a potential biomarker, we first explored its predictive
capabilities in lymphoblastoid cells derived from the
blood of C9ORF72- and sporadic ALS patients with
rapid and slowly progressive disease (Fig. 1d, Table 2).
C9ORF72-ALS patient samples were used at a previous
Fig. 2 Prioritisation and functional enrichment of genes modules. Gene co-expression modules associated with ALS neuropathology were identified using
WGCNA; modules are numbered 1–82. Modules were tested for enrichment with three assessment gene sets curated to represent rate of progression in
motor neurons (a) and lymphoblastoid cells (b), and upstream genetic association (c) with ALS. -log (p-value) refers to the p-value for enrichment of the
corresponding module number with the relevant assessment set as calculated by Fisher’s exact test. Only modules significantly enriched with each
assessment set (p-value <0.05) are plotted with respective p-values
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stage to prioritise the immune module but the sporadic
ALS patients comprise an entirely independent dataset.
By testing for biomarker performance of the immune
module in both datasets separately we aimed to reduce
the likelihood of a false positive result.
First we evaluated whether gene expression in the im-
mune module could predict ALS severity as indicated by
the time between onset of symptoms and death. Age of
onset and sex have been independently linked to prog-
nosis in ALS [38]. Clinical interventions such as artificial
respiratory support have also been shown to affect
survival but this data was not available. We fitted a Cox
proportional hazards model including age of symptom
onset, sex and disease duration (to nearest half-year,
Additional file 1: Figure S4) together with the top 15
principal components of gene expression in the im-
mune module. In both C9ORF72 and sporadic ALS, the
model was significantly predictive of disease severity
(Chi2; C9ORF72-ALS p = 0.01; sporadic ALS p = 0.004).
To further test the significance of this result we per-
formed an identical analysis using the negative control
module representing genes specifically expressed in
non-diseased motor neurons. The top 15 principal com-
ponents of gene expression in the control module were not
significantly predictive in either dataset (Chi2, p > 0.1).
Next, to determine if the module could be useful to
support personalised treatment based on classification,
we asked whether gene expression in the immune
module could effectively classify patients with rapid ver-
sus slowly progressing disease. Binomial logistic regres-
sion on expression of individual genes within the
immune module identified those genes which differenti-
ated lymphoblastoid cells from patients with rapid and
slowly progressive disease compared to the null model.
Fig. 3 Construction of the immune network independent of cell type by addition of globally co-expressed genes and protein-protein interacting
partners. The immune network module (module 27) contained 65 genes which was expanded to 77 genes by addition of globally co-expressed
genes and protein-protein interacting partners. Each gene is represented by a node and is labelled with its HUGO identifier. Genes originating
from module 27 are arranged on the left-side of the diagram; genes identified as globally co-expressed or protein-protein interacting partners are
arranged on the right-side of the diagram. Relationships between genes are represented as edges between nodes, either global co-expression
(purple) or protein-protein interaction (pink). Only genes with edges reaching statistical significance are shown. CEBPD, LILRA2 and ITGB2 (blue nodes),
represent a proposed blood-based biomarker; TREM2 (red node) protein measured in CSF correlates with disease duration in selected patients
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Fifteen of the immune module genes differentiated rapid
and slowly progressive C9ORF72-ALS cases; and in
sporadic ALS, 20 genes differentiated rapid and slowly
progressive cases (Additional file 2: Table S6). LILRA2,
ITGB2 and CEBPD (Fig. 3) were predictive in both
C9ORF72-ALS and sporadic ALS. Fitting binomial logistic
regression with leave-one-out cross validation confirmed
that a model combining expression of LILRA2, ITGB2 and
CEBPD was able to correctly classify patients by disease
severity more often than would be expected by chance
(85% of C9ORF72 and 60% of sporadic ALS classified cor-
rectly, Additional file 1: Figure S4). Interestingly LILRA2,
ITGB2 and CEBPD are expressed by microglia/macro-
phage cells (Additional file 2: Table S5).
Assessment of immune module as a potential biomarker
in CSF
CSF is frequently used to observe CNS-inflammation
[31]. We wished to determine if members of the im-
mune module may have potential as a biomarker in CSF.
CSF is relatively acellular and therefore suited to a
protein-level rather than gene expression quantification.
It was not technically feasible to assess all members of
the immune module. TREM2, a member of the immune
module (Fig. 3), had an available assay and known asso-
ciation with neurodegeneration [20, 34, 36, 47]. We
chose to evaluate soluble TREM2 in CSF as a potential
biomarker for ALS (Fig. 1d). Concentrations of soluble
TREM2, which is cleaved from the surface of microglia
[34], have been measured by ELISA in CSF [24, 34].
Genes thought to determine levels of soluble TREM2 in
CSF identified by genome-wide complex trait analysis
[36] (Additional file 2: Table S7), are enriched in the im-
mune module (Fisher’s exact test, p = 0.04).
Levels of soluble TREM2 were measured in CSF from
sporadic ALS patients with varying disease severity
(n = 46) and controls with normal CSF constituents
(n = 20) (Table 3). The effectiveness of TREM2 as a
biomarker was investigated in two ways; first, we ex-
amined whether levels of soluble TREM2 are altered
in ALS in comparison to healthy controls, and second, we
tested whether soluble TREM2 can classify rapid and
slowly progressive ALS. Levels of soluble TREM2 were
significantly higher in CSF from ALS patients compared
to controls (mean of 18 ng/ml compared to mean of 7 ng/
ml, Mann–Whitney p = 0.04, Fig. 4a). Levels of measured
soluble TREM2 in controls are comparable to other
studies [36, 47].
TREM2 has been implicated in stimulation of micro-
glia to clear Alzheimer’s-associated protein aggregates
[24]. We tested for enrichment of Alzheimer’s disease
GWA genes (Additional file 2: Table S8) within the im-
mune module and found that it is highly enriched
(Fisher’s exact test, p = 1.83E-07). From this we
postulate that the immune module captures a molecu-
lar response to neuropathology not just in ALS, but in
neurodegeneration more broadly.
In Alzheimer’s disease levels of soluble TREM2 are
higher in early phase disease [46, 47]. The same is true
in ALS: mean soluble TREM2 levels are three-times
higher in early disease compared to late stage disease
(mean soluble TREM2 in early disease = 36 ng/ml, mean
soluble TREM2 in late disease = 13 ng/ml, Fig. 4b).
Strikingly, in late stage disease levels of soluble TREM2
show a significant positive correlation with disease dur-
ation (Spearman rank correlation, p = 0.01, Fig. 4c). In
early disease there is not a significant correlation. Early
elevation of TREM2 expression may reflect an initial
immune response to deposition of pathological aggre-
gates which declines over time; higher levels of TREM2
in late disease may reflect a sustained neuroprotective
microglial response (Fig. 4d).
Discussion
Our analysis consisted of a data-driven systematic dis-
covery phase leading to discovery of gene modules
which were further evaluated in a biomarker assessment
phase. In the discovery phase (Fig. 1a–c), transcriptome-
wide gene expression changes in proportion to the de-
velopment of cytoplasmic proteinaceous inclusions in
ALS motor neurons allowed us to discover molecular
determinants of disease severity. Gene expression and
pathology counts were carried out in the same cell
population to avoid confounding by variation between
populations. The extent of pathology varies between
neuronal populations even within individual patients [3].
Transcripts found to be expressed in proportion to the
development of neuropathology were utilised to produce
45 modules of co-expressed genes. In a systematic
filtering process these modules were then prioritised by
demonstration of enrichment with independent mea-
sures of ALS biology. We discovered two gene modules
strikingly enriched with gene sets associated with rate of
ALS progression in both motor neurons and lympho-
blastoid cells, and also with ALS GWA genes.
In the biomarker assessment phase (Fig. 1d) we
selected one of the top scoring modules which showed
the highest enrichment with rate of progression genes in
lymphoblastoid cells, and was enriched with genes asso-
ciated with immune function. The majority of genes
within this module are expressed in microglia as op-
posed to other glial subtypes. Microglia are crucial for
clearance of protein aggregates [16, 51] which is bio-
logically consistent with our focus on motor neuron
pathology. Many genes within the immune module have
not been previously implicated in ALS, however others
have highlighted the role of neuroinflammation and
microglial activation in disease progression [10, 44, 45]
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making this module a good candidate for further investi-
gation. Given that CNS immune function can be ob-
served peripherally [18, 31], we tested the potential of
this module to be a prognostic biomarker in peripherally
accessible tissue.
In tissue derived from patient blood, we demonstrated
that expression of the immune module as a whole was sig-
nificantly associated with ALS disease duration. Moreover,
a three-gene panel comprising LILRA2, ITGB2 and
CEBPD was found to correctly classify individuals as
suffering from rapid or slowly progressive disease, inde-
pendent of both genetic background and clinical interven-
tion such as respiratory support. Measurement in a
relatively small number of patients relying on microarray
technology is a limitation of these data but a larger bio-
marker validation study is beyond the scope of this study.
CSF is also peripherally accessible. TREM2 is a member
of the immune module which has been previously linked
to both ALS pathogenesis [5] and microglial activation [6].
We investigated the potential for soluble TREM2 in CSF
to predict disease course in ALS patients with mixed
genetic background. Soluble TREM2 cleaved from the sur-
face of microglia has been proposed as a biomarker in
other neurological diseases including Alzheimer’s disease
and multiple sclerosis [20, 34, 36, 47]. We show that
soluble TREM2 levels are significantly elevated in ALS
compared to controls. Elevation is most marked in early
disease, as has been observed in Alzheimer’s disease
[46, 47]. Importantly, in patients where CSF was acquired
in late stage disease, higher concentrations of soluble
TREM2 are strongly associated with slower disease pro-
gression. Marked early elevation of TREM2 expression
may reflect an initial immune response to deposition of
pathological aggregates which declines over time. It is
hypothesised that patients with higher levels of TREM2 in
late disease have mounted a sustained neuroprotective
microglial response (Fig. 4d).
Loss-of-function (LOF) mutations in TREM2, which
have been linked to risk of Alzheimer’s disease [7, 23],
and ALS [5], reduce phagocytosis of aggregated protein
by microglia [24]. Reduced phagocytosis may be toxic to
stressed neurons and indeed TREM2 activity has been
positively associated with a neuroprotective microglial
phenotype [39]. Modulating microglial activity through
TREM2 has been proposed as a therapeutic target in
Alzheimer’s disease [53]. Our data suggests that this
therapeutic strategy may also be applicable in ALS. In
addition to TREM2, it is probable that our immune
module contains other determinants of neuropathology
relevant to neurodegeneration more broadly: consistent
with this the immune module is enriched with GWA
genes for both ALS and Alzheimer’s disease.
Conclusions
The role of microglia in neurodegeneration is controver-
sial. There is evidence for microglia mediated neurotoxicity
Fig. 4 Measurement of soluble TREM2 in CSF from ALS patients and controls. Soluble TREM2 levels were measured by ELISA in CSF from ALS
patients (n = 46) and controls (n = 20) who were age and sex matched. Levels of soluble TREM2 are significantly higher in ALS patients compared
to controls (Mann–Whitney, p < 0.05) (a). Stage of ALS at the time of sample was determined by the time from onset to sample compared to
time from onset to death (censored). Levels of soluble TREM2 are highest in early ALS (CSF sampled in <25th centile of disease course), intermediately
raised in late (>75th centile of disease course) and lowest in controls (b). Error bars show standard error. Levels of soluble TREM2 are positively correlated
with disease duration in late stage ALS (c). We suggest a model whereby CSF soluble TREM2 is elevated in early disease in all ALS patients but then
gradually reduces. In certain patients levels remain relatively high reflecting a prolonged neuroprotective microglial activation which leads to slower
disease progression (d)
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and neuroprotection. For example, [11C](R)-PK11195
positron emission tomography assay of microglial activa-
tion in motor cortex is positively correlated with burden of
upper motor neuron degeneration [49] but compromised
microglial function through LOF mutations in TREM2 in-
creases the risk of ALS [5]. To explain this controversy
microglia are thought to be capable of multiple phenotypes
which are variably neuroprotective and neurotoxic [1]. Our
immune module is derived by association with motor
neuron pathology and predicts ALS prognosis. The preva-
lence of microglial-expressed genes within this module
supports the possibility that there is a direct link between
microglial function and motor neuron death. The positive
correlation we have identified between soluble TREM2
concentration in CSF and a more benign ALS phenotype
supports the possibility of neuroprotection mediated by
microglial phagocytosis.
We have performed a scalable systematic, objective
discovery of potential predictive biomarkers and a po-
tential therapeutic target. Pathology-correlated gene ex-
pression in motor neurons has, for the first time in a
data-driven manner, identified microglial function as an
important determinant of ALS pathogenesis across a
broad spectrum of genetically heterogeneous patients
who all display TDP-43/p62 proteinopathy. Microglia
are implicated in neurodegenerative disease [10, 45] and
are thought to be responsible for clearance of protein
aggregates, clearly linking them to development of
neuropathology [16, 51]. We propose that phagocytosis
of protein aggregates by microglia is likely to be thera-
peutic and enhanced by TREM2 signalling, making
phagocytosis of protein aggregates by microglia an im-
portant focus for future translational research in ALS
and other neurodegenerative diseases.
Additional files
Additional file 1: Figures S1–S4. Contain plots of pathology counts in
ALS-motor neurons and details of the WGCNA analysis used to derive
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Additional file 2: Tables S1–S8. Contain gene lists used in the analysis.
(XLSX 317 kb)
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